Medicus Pharma (NASDAQ:MDCX) said Babar K. Rao, principal investigator of its SKNJCT-003 Phase 2 trial, will join the company’s leadership team during a business update webcast on March 26 following its fiscal 2025 Form 10-K filing.
Rao will discuss results from the randomized study evaluating doxorubicin delivered via the SkinJect microneedle platform for nodular basal cell carcinoma.
The trial showed 73% clinical clearance in the 200-microgram treatment cohort at Day 57, compared with 38% in the device-only arm, supporting further development of the minimally invasive therapy.